Business

March 21, 2014 12:14 PM

Canada approves Biogen Idec's hemophilia treatment

Canada approves Biogen Idec's Alprolix, the first new hemophilia med in 17 years. Alprolix is awaiting US approval and is manufactured in the Triangle, where Biogen employs 1,200 people.

Related content

Suggested for you

Comments

Videos

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos